<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02776371</url>
  </required_header>
  <id_info>
    <org_study_id>2016SDU-QILU-05</org_study_id>
    <nct_id>NCT02776371</nct_id>
  </id_info>
  <brief_title>Modified Non-clarithromycin Triple Therapy in Eradicating Helicobacter Pylori</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Helicobacter pylori (H. pylori) infects more than 50% of the population in the world(1),
      especially 47-66% in China.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the difference of eradication rates between 2 groups</measure>
    <time_frame>5 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the different rates of adverse events between 2 groups</measure>
    <time_frame>5 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">301</enrollment>
  <condition>Helicobacter Pylori Eradication Rate</condition>
  <arm_group>
    <arm_group_label>Modified non-clarithromycin triple therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>H.pylori infected patients treated with 20 mg esomeprazole twice a day, and 1g amoxicillin, 500 mg tinidazole three times a day for 10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequential therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>H.pylori infected patients treated with 20 mg esomeprazole and 1 g amoxicillin, twice daily for 5 days, followed by 20 mg esomeprazole, 500 mg clarithromycin, and 500 mg tinidazole, twice daily for the next 5 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Modified non-clarithromycin triple therapy</intervention_name>
    <description>H. pylori infected patients treated with 20 mg esomeprazole twice a day, and 1g amoxicillin, 500 mg tinidazole three times a day for 10 days.</description>
    <arm_group_label>Modified non-clarithromycin triple therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sequential therapy</intervention_name>
    <description>H. pylori infected patients treated with 20 mg esomeprazole and 1 g amoxicillin, twice daily for 5 days, followed by 20 mg esomeprazole, 500 mg clarithromycin, and 500 mg tinidazole, twice daily for the next 5 days.</description>
    <arm_group_label>Sequential therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who were intend to undergo upper endoscopy for any purpose and volunteered to
             written inform consent.

        Exclusion Criteria:

          -  negative in rapid urease test (RUT)

          -  previous standard eradication therapy for H. pylori;

          -  history of esophagectomy or gastrectomy;

          -  gastrointestinal malignancy;

          -  contraindications or allergic to study drugs;

          -  user of taking medicine that may affect the result of the study within 4 weeks (e.g.,
             proton-pump inhibitors, H2-receptor antagonists, bismuth or antibiotics etc.);

          -  cardiopulmonary, hepatic or renal insufficiency, and/or severe current diseases or
             malignancy;

          -  pregnant or lactating women;

          -  participants of other trial within the past 3 months;

          -  unwilling or unable to participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Yanqing, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qilu Hospital of Shandong University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Gastroenterology, Qilu Hospital, Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2016</study_first_submitted>
  <study_first_submitted_qc>May 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2016</study_first_posted>
  <last_update_submitted>November 9, 2016</last_update_submitted>
  <last_update_submitted_qc>November 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong University</investigator_affiliation>
    <investigator_full_name>Yanqing Li</investigator_full_name>
    <investigator_title>Vice president of Qilu Hospital</investigator_title>
  </responsible_party>
  <keyword>Helicobacter pylori</keyword>
  <keyword>Sequential therapy</keyword>
  <keyword>Modified non-clarithromycin triple therapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Tinidazole</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

